[go: up one dir, main page]

EP1689354A4 - Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques - Google Patents

Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques

Info

Publication number
EP1689354A4
EP1689354A4 EP04812275A EP04812275A EP1689354A4 EP 1689354 A4 EP1689354 A4 EP 1689354A4 EP 04812275 A EP04812275 A EP 04812275A EP 04812275 A EP04812275 A EP 04812275A EP 1689354 A4 EP1689354 A4 EP 1689354A4
Authority
EP
European Patent Office
Prior art keywords
cataracts
amelioration
macular degeneration
ophthalmic diseases
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812275A
Other languages
German (de)
English (en)
Other versions
EP1689354A2 (fr
Inventor
William L Matier
Ghanshyam Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Othera Holding Inc
Original Assignee
Othera Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othera Holding Inc filed Critical Othera Holding Inc
Publication of EP1689354A2 publication Critical patent/EP1689354A2/fr
Publication of EP1689354A4 publication Critical patent/EP1689354A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
EP04812275A 2003-11-20 2004-11-22 Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques Withdrawn EP1689354A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52380303P 2003-11-20 2003-11-20
PCT/US2004/039716 WO2005055926A2 (fr) 2003-11-20 2004-11-22 Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques

Publications (2)

Publication Number Publication Date
EP1689354A2 EP1689354A2 (fr) 2006-08-16
EP1689354A4 true EP1689354A4 (fr) 2010-07-14

Family

ID=34676585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812275A Withdrawn EP1689354A4 (fr) 2003-11-20 2004-11-22 Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques

Country Status (8)

Country Link
EP (1) EP1689354A4 (fr)
JP (1) JP2007527417A (fr)
KR (1) KR20070040326A (fr)
CN (1) CN101102770A (fr)
AU (1) AU2004296738A1 (fr)
CA (1) CA2546053A1 (fr)
IL (1) IL175498A0 (fr)
WO (1) WO2005055926A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
WO2006127592A2 (fr) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Amelioration des cataractes induites par vitrectomie
AU2007221271A1 (en) * 2006-02-22 2007-09-07 Othera Holding, Inc. Hydroxylamines and derivatives for the inhibition of complement activation
WO2008101195A2 (fr) * 2007-02-16 2008-08-21 Othera Holding, Inc. Inversion de la résistance à des médicaments dans une maladie néoplasique
CA2679066A1 (fr) * 2007-02-22 2008-08-28 Othera Holding, Inc. Composes d'hydroxylamine et leurs procedes d'utilisation
CA2707158A1 (fr) * 2007-11-28 2009-06-04 Revision Therapeutics, Inc. Modulateurs de stress oxydatif oculaire
EP2080513A1 (fr) * 2008-01-16 2009-07-22 Schraermeyer, Ulrich, Prof. Dr. rer. nat Tétrahydropyridoéthers pour le traitement de la DMA
CN102988331B (zh) * 2012-05-31 2015-02-04 管孝君 2-巯基-3-丁醇用于制备抗晶状体混浊产品的用途
JP6302091B2 (ja) * 2014-04-30 2018-03-28 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物および眼の疾患の処置におけるその使用
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
US20170246176A1 (en) * 2014-10-31 2017-08-31 Keio University Phacosclerosis inhibitor
EP3615086A4 (fr) 2017-04-27 2021-01-06 The Johns Hopkins University Compositions de dendrimères destinées à être utilisées en angiographie
US20200038355A1 (en) * 2017-04-28 2020-02-06 Case Western Reserve University Antioxidants for use in ophthalmic surgery
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327263A1 (fr) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Stimulation de la croissance des cheveux avec nitroxide et autres radicaux
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
WO2003096991A2 (fr) * 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration de l'evolution des cataractes et d'autres maladies ophtalmiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1447095A (en) * 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
WO1996015110A1 (fr) * 1994-11-15 1996-05-23 Moreno Paolini N-hydroxypiperidines en tant qu'intercepteurs de radicaux superoxyde
CA2414586C (fr) * 2000-06-29 2009-09-29 Mitsubishi Pharma Corporation Agent de traitement therapeutique des maladies du nerf optique et de maladies semblables
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
EP0327263A1 (fr) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Stimulation de la croissance des cheveux avec nitroxide et autres radicaux
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
WO2003096991A2 (fr) * 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration de l'evolution des cataractes et d'autres maladies ophtalmiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL-REMESSY AZZA B ET AL: "Neuroprotective effect of (-)DELTA9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: Involvement of peroxynitrite.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 5, 1 November 2003 (2003-11-01), pages 1997 - 2008, XP002584345, ISSN: 0002-9440 *
WANG MIN ET AL: "Tempol, superoxide dismutase mimic, ameliorates light-induced retinal degeneration", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, PJD PUBLICATIONS LTD, US, vol. 89, no. 3, 1 September 1995 (1995-09-01), pages 291 - 305, XP009114398, ISSN: 1078-0297 *
WERMUTH C G ET AL: "The Practice of Medicinal Chemistry , DESIGNING PRODRUGS AND BIOPRECURSORS I: CARRIER PROGRUGS", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1 January 1996 (1996-01-01), pages 671 - 696, XP002290286 *
ZIGLER J SAMUEL JR ET AL: "Tempol-H inhibits opacification of lenses in organ culture.", FREE RADICAL BIOLOGY & MEDICINE, vol. 35, no. 10, 15 November 2003 (2003-11-15), pages 1194 - 1202, XP002584344, ISSN: 0891-5849 *

Also Published As

Publication number Publication date
KR20070040326A (ko) 2007-04-16
JP2007527417A (ja) 2007-09-27
CA2546053A1 (fr) 2005-06-23
AU2004296738A1 (en) 2005-06-23
EP1689354A2 (fr) 2006-08-16
WO2005055926A2 (fr) 2005-06-23
WO2005055926A3 (fr) 2006-12-07
CN101102770A (zh) 2008-01-09
IL175498A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
EP1689397A4 (fr) Amelioration de la degenerescence maculaire et d&#39;autres maladies ophtalmiques
EP1689354A4 (fr) Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques
ZA200408449B (en) Amelioration of the development of cataracts and other opthalmic diseases
IL177284A0 (en) Management of ophthalmologic disorders, including macular degeneration
IL191148A0 (en) Optical devices and methods for selective and conventional photocoagulation of the retinal pigment epithelium
EG24420A (en) Treatment of ophthalmic conditions
TWI369996B (en) Ophthalmic compositions and methods for treating eyes
AU2001260197A1 (en) Selective corneal aberrometry
EP1933751A4 (fr) Chirurgie réfractive intrastromale par induction d&#39;un changement de forme de la cornée
AU2003248565A1 (en) Disposable undergarment and methods of making, using and marketing same
IL173351A0 (en) Therapy of ocular disorders
EP2083841A4 (fr) Traitement de la dégénération maculaire due au vieillissement et d&#39;autres maladies oculaires
EP1545555A4 (fr) Compositions et procedes de traitement de maladies des tissus epitheliaux et retiniens
GB0414772D0 (en) Ophthalmic eye preparation
GB0316745D0 (en) Artificial cornea
AU2002353487A1 (en) Herbal ophthalmic formulation for preventing cataract
GB0523961D0 (en) The treatment of ophthalmic diseases
AU2003292838A1 (en) Therapeutic agent for wet age-related macular degeneration
ZA200607713B (en) Management of opthalmologic disorders, including macular degeneration
HK1098067A (en) Management of ophthalmologic disorders, including macular degeneration
GB0523964D0 (en) The treatment of ophthalmic diseases
AU2003905690A0 (en) Extraocular Retinal Prosthesis
AU2004906179A0 (en) Extraocular retinal prosthesis
HK1094946A (en) Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
HK1093148A (en) Anti-cd20 therapy of ocular disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060620

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101AFI20070116BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTHERA HOLDING, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/12 20060101ALI20100528BHEP

Ipc: C07D 401/12 20060101ALI20100528BHEP

Ipc: C07D 211/94 20060101ALI20100528BHEP

Ipc: A61K 9/00 20060101ALI20100528BHEP

Ipc: A61P 39/06 20060101ALI20100528BHEP

Ipc: A61P 27/12 20060101ALI20100528BHEP

Ipc: A61P 27/06 20060101ALI20100528BHEP

Ipc: A61P 27/02 20060101ALI20100528BHEP

Ipc: A61K 38/06 20060101ALI20100528BHEP

Ipc: A61K 45/06 20060101ALI20100528BHEP

Ipc: A61K 31/4525 20060101ALI20100528BHEP

Ipc: A61K 31/198 20060101ALI20100528BHEP

Ipc: A61K 31/145 20060101ALI20100528BHEP

Ipc: A61K 31/445 20060101AFI20070116BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100914